Rationale: Siglec15 is an emerging target for normalization cancer immunotherapy.
However, pan-cancer anti-Siglec15 treatment is not yet validated and the potential role of …

Although immune checkpoint blockade (ICB) therapies have been approved for bladder
cancer (BLCA), only a minority of patients respond to these therapies, and there is an urgent …

Background Previous studies have explored the role of PD-L1 in the survival outcomes of
penile cancer patients with controversies existed. Thus, the meta-analysis was conducted to …

Background Penile cancer is rare among male malignancies. Various biomarkers have
been used to predict the prognosis of cancer, one of which is the neutrophil to lymphocyte …

Objectives There is an unmet need for therapeutically relevant biomarkers for advanced
penile squamous cell carcinoma (pSCC). Proposed immunohistochemistry (IHC)-based …

Background Lung cancer is one of the most lethal cancers worldwide, but studies have
shown that the higher the expression of programmed cell death protein 1 ligand 1 (PD-L1) in …

Purpose We evaluated the impact of examined lymph node (ELN) number on the prognosis
of stage II colon cancer after radical surgery and developed a novel prognostic scoring …

New tumor biomarkers open the potential for designing personalized therapy for penile
squamous cell carcinoma. Despite the initial promising results of some biomarkers …

Background To evaluate the overall survival (OS) and construct a nomogram to predict the
OS of patients with penile squamous cell carcinoma (PSCC). Methods This retrospective …

Background: Although neoadjuvant chemotherapy (NAC) has become the standard
treatment option for muscle invasive bladder carcinoma (MIBC), its application is still limited …